RBCC Visits Texas Genome-Mapping Target

NOKOMIS, Fla.--(BUSINESS WIRE)--

Since the new year began, Rainbow Coral Corp. (RBCC) has wasted no time in searching for new targets to add to its portfolio of projects for commercialization. Last week, the Companys executive leadership accepted an invitation to tour a genome-mapping facility in Houston with which RBCC could soon partner.

New healthcare innovations related to the human genome represent a target-rich area of interest for RBCC.The Texas company currently being reviewed performs tests to identify genetic markers in patients that can potentially boost or nullify the effects of certain medications.

Such testing could dramatically change the way medications are prescribed, potentially fostering a significant reduction in global health care costs.

Knowing specifics about an individuals genetic make-up can greatly assist a patients doctor in determining correct doses of medications as well as ruling out medications that could prove harmful, said RBCC CEO Patrick Brown. Genome mapping opens up a host of new possibilities for doctors and patients alike, and were very interested in the technologys economic potential.

As the company searches for its next partner, RBCCs biotech subsidiary Rainbow Biosciences remains close to a joint venture deal with Amarantus Bioscience, makers of exciting new diagnostic tools and therapies for neurological diseases such as Parkinsons.

Amarantus recently announced highly promising results in new animal trials of its forthcoming Parkinsons therapeutic, known as MANF.

For more information on RBCC and its biotechnology targets, please visitwww.rainbowbiosciences.com/investors.

Rainbow BioSciences is dedicated to developing new medical and research technology innovations to compete alongside companies such as Amgen Inc. (AMGN), Cell Therapeutics, Inc. (CTIC) and Abbott Laboratories (ABT).

Follow us on Twitter atwww.twitter.com/RBCCinfo.

Read more here:
RBCC Visits Texas Genome-Mapping Target